Report : Asia Pacific Peptide Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic, Innovative); Route of Administration (Parenteral, Oral, Mucosal, Pulmonary, Others); Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology); Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, Dermatology), and Country
Innovative Segment by type is estimated to lead the market growth during the forecast period
According to a new market research study of “Asia Pacific Peptide Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Type, Route of Administration, Synthesis Technology, Application and Country.” The Asia Pacific peptide therapeutics market is expected to reach US$ 10,565.67 Million by 2027 from US$ 4,986.73 Million in 2019; it is estimated to grow at a CAGR of 9.9% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific peptide therapeutics market and the factors driving market along with those that act as hindrances.
The peptide therapeutics market, by type, is segmented into generic, and innovative. The innovative segment held the largest share of the market in 2019, whereas the generic segment is anticipated to register the highest CAGR in the market during the forecast period. Peptides are naturally occurring biological molecules that play a prominent role in important biological activities. Continuous R&D activities in peptide therapeutics have discovered its benefits in tackling a range of chronic disorders, such as renal disorders, genetic conditions, oncology, and neurodegenerative conditions. Over 7,000 naturally occurring peptides have been identified in recent years, which have crucial roles in human physiology, including actions as neurotransmitters, hormones, ion channel ligands, and growth factors. The effectiveness of the outcomes of peptide therapies is generating investments in the development of new drugs. Also, increasing prevalence of metabolic and infectious diseases is one of the prominent factors expected to drive the peptide therapeutics market. An estimated 1.2 million Australians (4.9% of the total population) were suffering from diabetes in 2018, based on self-reported data from the Australian Bureau of Statistics. Hence, increase in investments in the development of new drugs for peptide therapies and applicability of therapies for treatment of viral infections and chronic diseases are expected to accelerate the growth of the peptide therapeutics market during the forecast period.
The growth of the Asia Pacific peptide therapeutics market is attributed to key driving factors, such as growing investments in peptide therapeutics and increasing prevalence of metabolic disorders and infectious diseases. However, operational limitations of peptides are expected to restrain the growth of the market during the forecast period.
Amgen Inc, Eli Lilly and Company and EVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies operating in the Asia Pacific peptide therapeutics market.
The report segments in Asia Pacific Peptide Therapeutics Market as follows:
By Route of Administration
By Synthesis Technology
- Solid Phase Peptide Synthesis (SPPS)
- Liquid Phase Peptide Synthesis (LPPS)
- Hybrid Technology
- Metabolic Disorder
- Cardiovascular Disorder
- Respiratory Disorder
- South Korea
- Rest of Asia Pacific
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org